CSPC Pharmaceutical Group ( (CHJTF) ) has released its Q4 earnings. Here is a breakdown of the information CSPC Pharmaceutical Group presented to its investors.
CSPC Pharmaceutical Group Limited is a Hong Kong-based company engaged in the research, development, manufacture, and sale of pharmaceutical products, particularly focusing on innovative drugs across various therapeutic areas.
In its latest earnings report for the year ending December 31, 2024, CSPC Pharmaceutical Group reported a decline in total revenue by 7.8% to RMB 29 billion, with significant decreases in both finished drugs and functional food sales. The company’s profit attributable to shareholders also saw a notable drop of 26.3% compared to the previous year.
Key financial highlights include a 7.4% decrease in revenue from finished drugs and a 22.2% drop in functional food sales. The company faced challenges due to centralized procurement price cuts, particularly affecting its oncology products. However, CSPC made strides in R&D, with increased investments leading to several new product launches and approvals, including innovative drugs in oncology and cardiovascular areas.
Looking ahead, CSPC Pharmaceutical Group remains focused on enhancing its R&D capabilities and expanding its international presence. The company plans to leverage AI technology for drug development and aims to increase its market share through strategic partnerships and licensing agreements with global pharmaceutical companies.